Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 3/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | FABP4 | P15090 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | FABP3 | P05413 | 1/20 | 0.32 |
| ▸ | FABP2 | P12104 | 1/20 | 0.32 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | CDC7 | O00311 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30967900 | 1.00 | HTR2A (0.50) | HTR2AHTR2CSLC6A2ROCK1NTSR1 | |
| SCHEMBL516662 | 0.86 | HTR7 (0.40) | HTR2AHTR2CSLC6A2HTR7PDE4B | |
| SCHEMBL28979 | 0.81 | HTR2A (0.49) | HTR2AHTR2CSLC6A2ROCK1FABP4 | |
| SCHEMBL2073701 | 0.79 | PRKCI (0.53) | HTR2AHTR2CNTSR1 | |
| SCHEMBL2502244 | 0.79 | KDM4E (0.36) | HTR2AHTR2CHTR7CYP19A1CDC7 | |
| SCHEMBL850727 | 0.79 | HTR2C (0.50) | HTR2AHTR2CSLC6A2SLC6A4CYP19A1 | |
| SCHEMBL3327014 | 0.79 | MAPT (0.33) | HTR2AHTR2C | |
| SCHEMBL29773 | 0.79 | HTR2A (0.50) | HTR2AHTR2CSLC6A2SLC6A4CYP19A1 | |
| SCHEMBL30949143 | 0.79 | HTR2A (0.50) | HTR2AHTR2CSLC6A2SLC6A4CYP19A1 | |
| SCHEMBL29119 | 0.77 | HTR2C (0.54) | HTR2CSLC6A2ROCK1SLC6A4HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304558-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-10-02 | — | — | US | disclosed |
| US-12391674-B2 | Heterocyclic compounds for the treatment of epilepsy | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-08-19 | — | — | US | disclosed |
| US-20240279220-A1 | INDOLE COMPOUNDS AND METHODS OF USE | SIONNA THERAPEUTICS INC. | 2024-08-22 | — | — | US | disclosed |
| EP-4396179-A1 | INDOLE COMPOUNDS AND METHODS OF USE | GENZYME CORPORATION (US) | 2024-07-10 | — | — | EP | disclosed |
| CN-118201919-A | Indole compounds and methods of use | 健赞公司 | 2024-06-14 | — | — | CN | disclosed |
| US-11718588-B2 | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | GALAPAGOS NV (BE) | 2023-08-08 | — | — | US | disclosed |
| US-11718588-B2 | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | GALAPAGOS NV (BE) | 2023-08-08 | — | — | US | disclosed |
| WO-2023034992-A1 | INDOLE COMPOUNDS AND METHODS OF USE | GENZYME CORPORATION (US) | 2023-03-09 | — | — | WO | disclosed |
| US-20210403456-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-12-30 | — | — | US | disclosed |
| US-20210309614-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2021-10-07 | — | — | US | disclosed |
| US-5637593-A | MIGRAINE; HYPOTENSIVE AGENTS | SMITHKLINE BEECHAM PLC (GB) | 1997-06-10 | — | — | US | disclosed |
| US-5612360-A | AROMATIC N-HETEROCYCLIC COMPOUNDS AS HYPOTENSIVE AGENTS WITH ACID GROUPS, SULFONYLCARBOXAMIDES OR TETRAZOLE GROUPS | ELI LILLY AND COMPANY (US) | 1997-03-18 | — | — | US | disclosed |
| US-5583149-A | TREATING VASCULAR HEADACHES | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-12-10 | — | — | US | disclosed |
| US-5569768-A | USEFUL IN TREATING HYPERTENSION, CONGESTIVE HEART FAILURE, GLAUCOMA AND RENAL INSUFFICIENCY | ELI LILLY AND COMPANY (US) | 1996-10-29 | — | — | US | disclosed |
| US-5556981-A | Angiotensin II antagonist intermediates | ELI LILLY AND COMPANY (US) | 1996-09-17 | — | — | US | disclosed |
| EP-0687267-A1 | PYRROLO-PYRIDINE DERIVATIVES | MERCK SHARP & DOHME LTD. (GB) | 1995-12-20 | — | — | EP | disclosed |
| US-5468768-A | FOR TREATING VASCULAR HEADACHES | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-11-21 | — | — | US | disclosed |
| EP-0666258-A1 | Indolylcycloaklanylamin- und Indolylcycloalkenylamine derivatives, their preparation and their use as anti-migraine agents | Bristol-Myers Squibb Company (US) | 1995-08-09 | — | — | EP | disclosed |
| WO-1994020459-A2 | PYRROLO-PYRIDINE DERIVATIVES AS DOPAMINE RECEPTOR LIGANDS | MERCK SHARP & DOHME LIMITED (GB) | 1994-09-15 | — | — | WO | disclosed |
| EP-0574174-A2 | Angiotensin II antagonists | ELI LILLY AND COMPANY (US) | 1993-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279220-A1 | INDOLE COMPOUNDS AND METHODS OF USE | CFTR, INMT, IDO1 | HTR2A 64/4885HTR2C 38/4885SLC6A2 159/4885 |
| US-12391674-B2 | Heterocyclic compounds for the treatment of epilepsy | SLC6A11, SCN1A, SCN1B | HTR2A 2817/4885HTR2C 1821/4885SLC6A2 751/4885 |
| US-20210403456-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY | SLC6A11, SCN1A, SCN1B | HTR2A 2817/4885HTR2C 1821/4885SLC6A2 751/4885 |
| US-20210309614-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | ADAMTS1, ADAMTS5, ADAMTS7 | HTR2A 2074/4885HTR2C 2380/4885SLC6A2 4870/4885 |
| US-11718588-B2 | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | ADAMTS1, ADAMTS5, ADAMTS7 | HTR2A 2074/4885HTR2C 2380/4885SLC6A2 4870/4885 |
| US-20250304558-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY | SLC6A11, SCN1A, KCNH1 | HTR2A 3479/4885HTR2C 2389/4885SLC6A2 1047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.